Answers are grounded in this paper and cite their sources.
Parkinson’s disease (PD) is a progressive neurological condition characterized by degeneration of dopaminergic neurons in the substantia nigra, accompanied by α-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation, ultimately leading to hallmark motor symptoms including tremors and bradykinesia. RNA-based therapeutics are an emerging avenue for the treatment of PD due to their ability to modulate gene expression and therefore address the underlying molecular mechanisms driving disease progression. These approaches may modulate gene expression in key PD cell types. RNA-based therapeutics have been used to target dopaminergic neurons to strategically downregulate α-synuclein aggregation, balance growth signaling, inhibit apoptosis, or alleviate mitochondrial stress. Some strategies work to decrease neuroinflammation through microglia targeting. Additionally, some strategies seek to regulate dopamine signaling within serotonergic neurons and striatal medium spiny neurons. In this review, we summarize diverse RNA modalities that have been leveraged to address PD pathophysiology and explore nonviral carriers that have emerged to facilitate RNA delivery into target cells. We then discuss RNA-based therapeutic targeting strategies in preclinical and clinical studies and examine the trajectory of the field as these nanomedicines are increasingly applied to the treatment of PD.
No takes yet. Share an insight, caveat, or question.
Kiehl et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: